Bayer's Legal Clock Resets as Q2 Results Fuel a Wave of Analyst Upgrades

Bayer's glyphosate settlement hearing pushed to September, but Q2 net profit of €219M and strong Crop Science results signal recovery despite cash flow dip.

The calendar keeps shifting for Bayer's multibillion-dollar glyphosate settlement, but the underlying trajectory — both in court and on the balance sheet — is starting to look more favorable for the Leverkusen-based group. A federal judge in Missouri has pushed back the final approval hearing for the $7.25 billion class-action settlement, this time to September 10, according to Reuters, after the court was flooded with withdrawal requests from plaintiffs seeking to exit the deal. The secondary report cites September 14 as the new date, with the postponement jointly requested by Monsanto and plaintiffs' attorneys to allow the settlement administrator more time to process opt-out applications. Either way, the original August 19 slot is off the table, and the procedural delay does nothing to alter the fundamental direction of the case.

What does shift the narrative is the legal backdrop. The US Supreme Court's 7-2 ruling in the Durnell case back in June — establishing that federal law preempts state-level claims over missing warning labels on glyphosate products — continues to strengthen Bayer's hand. CEO Bill Anderson has pointed to the decision as a cornerstone of the company's containment strategy, which he describes as on track with key milestones ahead.

A Return to Profitability

The operational story is giving analysts just as much to work with. Bayer's first-half report, published Tuesday, showed currency- and portfolio-adjusted revenue growth of 2.2 percent to €10.872 billion, with EBITDA before special items up 1.9 percent to €2.144 billion. The second quarter marked a return to the black: net income of €219 million, reversing a €199 million loss in the same period last year. Core earnings per share, however, slipped 16.7 percent to €0.95.

The engine behind the beat was Crop Science. Segment revenue climbed 3.5 percent to €4.910 billion, while EBITDA before special items surged 30.2 percent to €902 million. Soybean Seed & Traits led the charge with a 16.9 percent gain, and Cotton Seed rebounded sharply — up 69.2 percent — following the return of the Dicamba label in the US. Pharmaceuticals were more subdued: revenue held nearly flat at €4.458 billion, but EBITDA before special items fell 3.6 percent to €1.055 billion. The segment's growth drivers, Nubeqa and Kerendia, combined for €1.2 billion in quarterly sales, a 69 percent jump year-on-year, with Nubeqa alone up 64 percent to €880 million.

The Cash Flow Caveat

Not everything is moving in the right direction. Free cash flow came in at minus €371 million for the quarter, versus a positive €125 million a year earlier, reflecting higher litigation-related payments. Net financial debt stood at €33.647 billion as of June 30. Yet management has taken a more optimistic view of the year-end figure, trimming the forecast to €29–30 billion from a prior €32–33 billion range — helped along by the July agreement with Apollo Global Management, which is taking a minority stake in Bayer's contraception business for €3.0 billion in equity.

Analysts Reach for New Targets

The market's response has been swift and broadly bullish. DZ Bank's Peter Spengler lifted his fair value from €54.00 to €60.00 on Friday, reiterating a buy recommendation on the back of the operational stabilization. Goldman Sachs' James Quigley had already moved his price target from €62.50 to €63.50 on Wednesday, keeping a "Buy" rating after the better-than-expected quarterly numbers. UBS followed on Thursday, raising its target from €52.00 to €62.00, with analyst Weston citing a core operating result that beat consensus by roughly 10 percent. JPMorgan held its "Overweight" stance at €50.00, reading the quarter as evidence of an operational inflection point. Barclays also chimed in with an upgraded or confirmed stance, per the reports.

Not everyone is convinced. Jefferies' Michael Leuchten remains the cautious voice in the room, holding his price target at €46.00 with a "Hold" rating, pointing to the group's still-elevated net debt.

Market Momentum

The share price has been tracking the improving sentiment. On Friday, Bayer closed at €49.90, up 1.05 percent on the day, and sits comfortably above its 50-day moving average of €44.16. Over the past twelve months, the stock has gained roughly 95.65 percent — a reflection of gradually rebuilding confidence in both the legal and operational fronts. Still, it remains about 7.35 percent below its 52-week high of €53.86, touched in early July.

The next major catalyst is already on the calendar: the September hearing in Missouri, which will determine whether the settlement receives final approval. Beyond that, investors will be watching the third-quarter numbers due November 3, where analysts are penciling in revenue of around €9.9 billion and earnings per share of €0.52.